Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ferroptosis is a Physiologic Vulnerability of Iron-Recycling Macrophages.

bioRxiv : the preprint server for biology·2026
Same author

Validation of the Standardized Outcomes in Nephrology - Life Participation (SONG-LP) Instrument in People Receiving Dialysis.

Kidney international reports·2026
Same author

Towards patient-centered healthcare: a scoping review of soft skills training in medical schools.

BMC medical education·2026
Same author

Hypomorphic biliverdin reductase a mutations define bilirubin anti-malarial threshold.

iScience·2026
Same author

Recurrent pregnancy loss: systematic review and meta-analysis of overall prevalence and the distribution of major etiological categories.

Frontiers in medicine·2026
Same author

Implementation strategies of team-based learning in undergraduate medical curricula: a scoping review.

BMC medical education·2026

Related Experiment Video

Updated: Apr 12, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.6K

Erlotinib and brain metastases.

Fernando Barata1, Teresa Costa1, Ana Figueiredo1

  • 1Serviço de Pneumologia. Centro Hospitalar de Coimbra.

Revista Portuguesa De Pneumologia
|May 14, 2015
PubMed
Summary

Erlotinib shows promise in treating brain metastases for non-small cell lung cancer (NSCLC) patients who have not responded to chemotherapy. This EGFR-targeted therapy offers a potential new strategy for managing this challenging aspect of NSCLC.

Keywords:
Erlotinibbrain metastasiscancro do pulmãolung cancermetástase cerebral

More Related Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.6K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.9K

Related Experiment Videos

Last Updated: Apr 12, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.6K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.6K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.9K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Brain metastases are a significant cause of mortality in non-small cell lung cancer (NSCLC).
  • Systemic treatment options for NSCLC brain metastases are limited, with poor outcomes after whole brain radiotherapy.
  • Current systemic therapies are often ineffective for brain metastases in advanced NSCLC.

Purpose of the Study:

  • To report on the efficacy of erlotinib in patients with non-small cell lung cancer (NSCLC) and brain metastases.
  • To investigate the potential of EGFR-associated tyrosine kinase inhibitors as a treatment strategy for NSCLC brain metastases.
  • To highlight the need for further research into erlotinib's role in managing differential responses in NSCLC.

Main Methods:

  • Two cases of non-small cell lung cancer (NSCLC) with brain metastases were treated with erlotinib 150mg/m2 orally daily after chemotherapy progression.
  • Response of brain metastasis and thoracic lesions to erlotinib was assessed.

Main Results:

  • Complete response of brain metastases was observed in both patients treated with erlotinib.
  • Partial response of thoracic lesions was noted in the patients.
  • Erlotinib demonstrated sensitivity in treating brain metastases, suggesting potential efficacy.

Conclusions:

  • Erlotinib may be a feasible and effective strategy for managing brain metastases in NSCLC patients.
  • EGFR-targeted tyrosine kinase inhibition shows promise for NSCLC patients with brain metastases.
  • Further studies are warranted to explore erlotinib's use in cases with differential treatment responses.